Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
December 4, 2024 6:54 AM ESTChardan Capital Markets analyst Geulah Livshits raised the price target on Senti Biosciences, Inc. (NASDAQ: SNTI) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "On 3 December, Senti Biosciences hosted a call to discuss initial data from the phase I trial of its... More



